BioWorld

July 23, 2008

$125M Deal Sends Mirus Bio Into the Roche RNAi Camp

Roche Holding AG, fresh off its $44 billion offer for Genentech Inc., moved to accelerate its research into RNAi gene silencing technology with the acquisition of Mirus Bio Corp. for $125 million. (BioWorld Today) Read More

BioMarin, Summit Partner for Duchenne Drug in $143M Deal

Biogen's Strong 2nd Quarter Helped by Tysabri Sales

Depomed Gets $12M Up Front in Diabetes Deal with Santarus

Other News To Note

Clinic Roundup

Appointments And Advancements

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 21, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 21, 2026.

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...